A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says
Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati
Benzinga’s Top Ratings Upgrades, Downgrades For September 13, 2022
Upgrades
See all analyst ratings upgrades.
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib)…
Outlook Therapeutics Shares Pop After Filing US Application For Its Lead Eye Disease Candidate
Outlook Therapeutics Inc (NASDAQ:OTLK) has re-submitted its marketing application to the FDA, seeking approval for ONS-5010 for wet age-related macular degeneration…
82 Biggest Movers From Yesterday
Gainers
Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday.
62 Biggest Movers From Yesterday
Gainers
Missfresh Limited (NASDAQ: MF) jumped 51.1% to close at $0.2450 on Wednesday.
77 Biggest Movers From Yesterday
Gainers
TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners.
Outlook Therapeutics Announces FDA Has Requested Additional Information In Order To Complete Filing Of Co.’s BLA For ONS-5010/ LYTENAVA
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in